SCHEMBL26810960

SCHEMBL26810960

Cn1cc2ccc(-c3cc(Oc4ccccc4)nc(NS(=O)(=O)c4ccccc4)n3)cc2n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ MAPT P10636 3/20 0.42
▸ GPR39 O43194 1/20 0.38
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ ATM Q13315 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ PGR P06401 2/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ KDM4E B2RXH2 3/20 0.37
▸ ALDH1A1 P00352 3/20 0.37
▸ CNR1 P21554 1/20 0.37
▸ GAA P10253 2/20 0.36
▸ PKM P14618 1/20 0.36
▸ LMNA P02545 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26810982 0.83 MAPT (0.50) TSHRSMN1; SMN2MAPTGPR39MEN1
SCHEMBL26810924 0.81 SMN1; SMN2 (0.48) TSHRSMN1; SMN2MAPTGPR39KMT2A
SCHEMBL26806813 0.81 MAPT (0.61) TSHRSMN1; SMN2MAPTGPR39MEN1
SCHEMBL26810935 0.80 SMN1; SMN2 (0.54) TSHRSMN1; SMN2MAPTGPR39MEN1
SCHEMBL26810763 0.79 TSHR (0.50) TSHRSMN1; SMN2MAPTGPR39MEN1
SCHEMBL26810912 0.78 SMN1; SMN2 (0.55) TSHRSMN1; SMN2MAPTPGRMAPK1
SCHEMBL26810798 0.78 TSHR (0.52) TSHRSMN1; SMN2MAPTGPR39MEN1
SCHEMBL26810868 0.78 MAPT (0.53) TSHRSMN1; SMN2MAPTGPR39MEN1
SCHEMBL26810905 0.78 SMN1; SMN2 (0.54) TSHRSMN1; SMN2MAPTGPR39MEN1
SCHEMBL26810773 0.78 MAPT (0.52) TSHRSMN1; SMN2MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B TSHR 1755/4885SMN1; SMN2 4847/4885MAPT 4864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback